Searchable abstracts of presentations at key conferences in endocrinology

ea0025p223 | Pituitary | SFEBES2011

Mortality in cushing’s disease: stoke-on-trent data and meta-analysis

Clayton Richard , Raskauskiene Diana , Reulen Raoul , Jones Peter

There are very limited data on long-term mortality in pituitary ACTH dependent Cushing’s disease (CD).We report on our data from Stoke-on-Trent, UK, spanning 50 years and provide a meta-analysis of six other reports which addressed mortality of CD. Case records of 60 CD patients from 1958-31 Dec 2009 from Stoke-on-Trent were reviewed. The standardised mortality ratio (SMR) overall and separately for patients in remission and having persistent diseas...

ea0024oc2.4 | Oral Communications 2 (Brief Communications) | BSPED2010

Morbidity and Mortality of Infants with Salt Wasting Congenital Adrenal Hyperplasia in an Unscreened Population

Hird B E , Patel L , Tobi S , Clayton P E

Due to the non-specificity of symptoms in male neonates affected by salt-wasting (SW) CAH, it is hypothesised that a proportion die prior to diagnosis in countries lacking a newborn screening (NBS) programme, such as the UK. The aim of this study was to analyse 17-hydroxyprogesterone (17-OHP) in stored NBS blood spot samples, to detect undiagnosed cases of CAH. Samples were retrieved from storage for neonates who were born between 1994 and 2006, who subsequently died before 7 ...

ea0023oc1.2 | Oral Communications 1 | BSPED2009

Altered GH/IGF1 signalling in children born small for gestational age without catch up growth

Butcher Imogen , Whatmore Andrew , Murray Philip , Westwood Melissa , Clayton Peter

Background: Infants born small for gestational age (SGA) usually show catch-up growth during the first few years of post-natal life. However, some infants remain small and little is known about the factors governing their growth failure. GH and IGF1 receptor mutations only account for a minority of cases. We have now initiated an in vitro assessment of signalling molecules downstream of these receptors and evaluation of cell growth characteristics.<p class="abstext"...

ea0021p227 | Growth and development | SFEBES2009

Altered responses to GH and IGF1 in children born small for gestational age without post-natal catch up growth

Butcher Imogen , Whatmore Andrew , Murray Philip , Westwood Melissa , Clayton Peter

Background: Infants born small for gestational age (SGA) usually show catch up growth within the first few years of life. However in the UK ~1500 SGA children each year remain small, with no clear endocrine cause with rare genetic syndromes accounting for only a minority of cases. In order to define growth factor activation in these children we have initiated an assessment of cell growth and signalling in response to GH and IGF1 in fibroblast cell lines....

ea0021p244 | Pituitary | SFEBES2009

Management of non-functioning pituitary adenomas in a University Hospital: aretrospective analytical audit

Varadhan Lakshminarayanan , Mukherjee Arjun , Brown Maureen , Clayton Richard , Hanna Fahmy

Introduction: Pituitary tumors account for 15% of all intracranial neoplasms and could remain asymptomatic for a significant period. We conducted a retrospective analysis to assess pattern of referrals and management of non-functioning pituitary adenomas at our tertiary referral centre.Methods: Data was collected on referrals for NFA received at our university hospital from 2005 to 2008. Medical records, radiology reports and endocrine department data we...

ea0019p195 | Growth and development | SFEBES2009

Delayed puberty: an occult systemic cause

Manjunatha RS , Varughese G , Varadhan L , Clayton RN

We report a 17-year-old male who presented with symptoms of absent secondary sexual characteristics, decreased appetite and infrequent non-specific abdominal pain. He had no complaints of headache, altered sense of smell or colour blindness. His other siblings had normal growth.On examination, he had normal male body habitus, height (157 cm), no gynaecomastia, axillary and beard hair (tanner stage 1) pubic hair (tanner stage 2), testes (12 ml bilaterally...

ea0019p197 | Growth and development | SFEBES2009

Altered IGF-I signalling in children born small for gestational age without catch up growth

Butcher I , Whatmore A , Murray P , Westwood M , Clayton P

Background: Infants born small for gestational age (SGA) usually show catch-up growth during the first few years of post-natal life. However, some infants remain small and little is known about the factors governing their growth failure. IGF-I receptor mutations account for a minority of cases therefore we have initiated an assessment of signalling molecules downstream of the receptor.Method: Skin biopsies were obtained with local ethics approval from he...

ea0013p60 | Clinical practice/governance and case reports | SFEBES2007

Short Synacthen Test (Standard and Low dose): Do we need multiple cortisol samples?

Kela Ram , Tahrani Abd , Varughese George , Clayton R , Hanna FWF

Aim: This study was aimed to assess the need for multiple cortisol samples in ruling out adrenal insufficiency by standard dose Short Synacthen Tests (SST) and Low Dose Short Synacthen Tests (LDSST).Method: We assessed the lab results of 767 patients who attended Metabolic Unit of a University Hospital in the UK from 1999 to 2006 for assessment of adrenal reserve. In LDSST, serum cortisol was measured at 0, 30 and 40 min after administration of 1 mcg of ...

ea0013p71 | Clinical practice/governance and case reports | SFEBES2007

Psychosis in a patient with acromegaly: Implications for clinical practice

Kings R , Foo L , Varughese GI , Tahrani AA , Clayton RN

We report of a 71-year-old gentleman first diagnosed with acromegaly in 1981. He was initially treated with hypophysectomy and radiotherapy and subsequently bromocriptine therapy; requiring increments in the dose over the next ten-years (1981–1991) by which time he remained on maintenance dose of 10mgs thrice-daily. Bromocriptine was tolerated well and the patient had no side effects. Treatment was weaned off due to improvement in patient’s symptoms and growth hormon...

ea0013p128 | Growth and development | SFEBES2007

Growth in Growth Hormone (GH) deficient dwarf rats is enhanced by variable dose GH treatment

Maqsood Arfa , Whatmore Andrew , Westwood Melissa , Clayton Peter

Good growth in children is associated with large, disordered, fluctuations in GH levels from week to week (Gill et al., 1999; Gill et al., 2001). However, GH treatment regimens are restricted to daily fixed doses which may not provide optimal growth. We have used GH-deficient dwarf rats (dw/dw) to test our hypothesis that variable GH dosing will enhance growth.Six week old, male dwarf rats (16 per group) were treated for 6 weeks with either...